Overview of secondary liver cancer care pathways, key treatment steps, and the situations where dendritic cell treatment may be discussed as a selected option.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2025 Earnings Call Transcript March 5, 2026 TriSalus Life Sciences, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.13.

A local hospital is using new technology to remove liver cancer without invasive surgery. It’s a word that no one ever wants to hear. “He found the cancer,” Paul Montgomery said. In 2022, Paul ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Q4 2025 earnings call recap: 60% revenue growth, 2026 guidance of $60–$62M, PEDD/TriNav expansion, funding and risks—read now.

February 11 and Cape Town has long held a significant place in South African history. From the 1990 release of Nelson Mandela from Victor Verster Prison, marking a turning point in the nation’s fight ...

Significant negative impact expected from the situation in Raleigh on revenue, profitability, cash generation and group indebtedness with a probable risk of covenant breach on June 30, 2026 No ...